Alexion Pharmaceuticals (ALXN)

Add to Watchlists
Create an Alert
127.57 +1.76  +1.40% NASDAQ Jun 22, 20:00 Delayed 2m USD

Alexion Pharmaceuticals Research and Development Expense (Quarterly):

176.60M for March 31, 2018
View 4,000+ financial data types
View Full Chart

Alexion Pharmaceuticals Research and Development Expense (Quarterly) Chart

Export Data
Save Image
Print Image

Alexion Pharmaceuticals Historical Research and Development Expense (Quarterly) Data

View and export this data going back to 1995. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
March 31, 2018 176.60M
Dec. 31, 2017 265.40M
Sept. 30, 2017 195.00M
June 30, 2017 199.00M
March 31, 2017 219.50M
Dec. 31, 2016 206.20M
Sept. 30, 2016 195.00M
June 30, 2016 180.00M
March 31, 2016 176.00M
Dec. 31, 2015 191.06M
Sept. 30, 2015 165.66M
June 30, 2015 131.69M
March 31, 2015 221.08M
Dec. 31, 2014 129.33M
Sept. 30, 2014 100.66M
June 30, 2014 92.55M
March 31, 2014 191.46M
Dec. 31, 2013 85.78M
Sept. 30, 2013 88.21M
June 30, 2013 68.56M
March 31, 2013 74.54M
Dec. 31, 2012 63.41M
Sept. 30, 2012 54.28M
June 30, 2012 59.64M
March 31, 2012 45.41M
Dec. 31, 2011 34.40M
Sept. 30, 2011 36.57M
June 30, 2011 35.65M
March 31, 2011 30.81M
Dec. 31, 2010 27.18M
Sept. 30, 2010 25.15M
June 30, 2010 23.69M
March 31, 2010 22.37M
Dec. 31, 2009 23.22M
Sept. 30, 2009 21.32M
June 30, 2009 18.29M
March 31, 2009 19.09M
Dec. 31, 2008 15.28M
Sept. 30, 2008 14.87M
June 30, 2008 16.82M
March 31, 2008 15.61M
Dec. 31, 2007 15.64M
Sept. 30, 2007 16.91M
June 30, 2007 15.20M
March 31, 2007 21.22M
Dec. 31, 2006 17.34M
Sept. 30, 2006 21.20M
June 30, 2006 23.46M
March 31, 2006 21.21M
Oct. 31, 2005 20.28M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

About R&D Expense

R&D expenses are a line item from many companies' income statements.

R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More


ALXN Research and Development Expense (Quarterly) Benchmarks

Biomarin Pharmaceutical 183.95M
Vertex Pharmaceuticals 310.55M
Regeneron Pharmaceuticals 498.59M

ALXN Research and Development Expense (Quarterly) Range, Past 5 Years

Minimum 68.56M Jun 2013
Maximum 265.40M Dec 2017
Average 163.94M

ALXN Research and Development Expense (Quarterly) Excel Add-In Codes

  • Metric Code: r_and_d_expense
  • Latest data point: =YCP("ALXN", "r_and_d_expense")
  • Last 5 data points: =YCS("ALXN", "r_and_d_expense", -4)

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.




Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{}} No credit card required.

Already a subscriber? Sign in.